The CSL (ASX:CSL) share price is down 9% in a month, here's why

This biotech giant's shares have been out of form recently…

| More on:
asx share price fall represented by woman shrugging

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been a poor performer over the last few weeks.

Since this time last month, the biotherapeutics company's shares are down 9%.

This compares to a 1.5% gain by the S&P/ASX 200 Index (ASX: XJO) over the same period.

Why is the CSL share price out of form?

The weakness in the CSL share price over the last 30 days appears to have been driven by a couple of mixed broker notes.

One of those came from the team at Citi on 23 June. Its analysts downgraded CSL shares to a neutral rating from buy on valuation grounds following a period of outperformance. Citi held firm with its $310.00 price target.

A few days later CSL was hit with another broker downgrade. This time it came from the team at Credit Suisse. According to that note, its analysts downgraded CSL's shares to a neutral rating and cut the price target on them to $310.00.

Credit Suisse made the move on the belief that the market had not taken into account potential margin weakness caused by tough plasma collection conditions. It suspects that the recovery could take longer than expected due to continued pressure on collections, particularly after the US prevented Mexicans from crossing the border to donate.

The broker suspects that the gross margin of its CSL Behring business could fall to 54.1% in FY 2022. This compares to 61.2% in FY 2020.

Is this a buying opportunity?

Given that the CSL share price has now fallen to $277.72, the price targets of both Citi and Credit Suisse offer decent upside of 11.5% over the next 12 months.

In addition, the team at UBS still have a buy rating and $330.00 price target on the company's shares. This implies potential upside of almost 19% over the next 12 months.

So, while the CSL share price has underperformed over the last 30 days, the next 30 could be more positive. Just as long as its full year results in August don't contain any nasty surprises.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »